Introduction:

Patients with severe mental illness have a lower life expectancy, reduced by 10-25 years compared to the general population. The development of metabolic syndrome due to antipsychotic treatment increases the risk of type two diabetes mellitus (T2DM) by five-fold and increases the risk of cardiovascular disease by two-fold over 5-10 years of antipsychotic therapy. Understanding how Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) at the dose for T2DM can affect antipsychotic-induced weight gain (AIWG) is significant and is an area that has not been reviewed before.

Research Question or Hypothesis:

The primary aim of this study is to investigate the effects of GLP-1 RAs on body weight in patients with T2DM who experienced AIWG. The goal is to understand if GLP-1 RAs, at the usual doses used for T2DM treatment, can reverse, or reduce, AIWG.

Study Design:

This study is a controlled retrospective systematic chart review and analysis.

Methods:

The patient chart data were collected from electronic medical health records at the Codman Square Health Center between June 1, 2024 and July 25, 2024. The study group consisted of patients with T2DM and AIWG taking a GLP-1 RA at T2DM doses. The control group consisted of patients not taking a GLP-1 RA but otherwise meeting the same criteria. The primary outcome is absolute weight-loss on a continuous scale in kg during the period of treatment with the GLP-1 RA in the study versus control group. The weight loss results will be divided into subgroups for analysis between non-clinically significant weight-loss (0-5%) and clinically significant weight loss (≥ 5%). A chi-square analysis will be done to see if there are significantly more patients losing a clinically significant amount of weight on the study treatment vs control.  Overall experiment-wise alpha levels will be set at 0.05. 

Results:

To be determined.

Conclusion:

To be determined.